TGR-1202: Phase I started

TG Therapeutics began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-daily oral TGR-1202 in combination with once-daily oral Imbruvica ibrutinib in about 60 patients. TG Therapeu...